Osteogenic effects of a potent Src-over-Abl-selective kinase inhibitor in the mouse.
Murrills RJ, Fukayama S, Boschelli F, Matteo JJ, Owens J, Golas JM, Patel D, Lane G, Liu YB, Carter L, Jussif J, Spaulding V, Wang YD, Boschelli DH, McKew JC, Li XJ, Lockhead S, Milligan C, Kharode YP, Diesl V, Bai Y, Follettie M, Bex FJ, Komm B, Bodine PV.
Murrills RJ, et al.
J Pharmacol Exp Ther. 2012 Mar;340(3):676-87. doi: 10.1124/jpet.111.185793. Epub 2011 Dec 9.
J Pharmacol Exp Ther. 2012.
PMID: 22171089